Skip to main content
AmigoFish

Pharmaceutical Executive Daily: FDA Approves Tecentriq

From Pharmaceutical Executive · · 2 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.

Back to Pharmaceutical Executive · Report a problem